Patient-Derived Antibody Appears to Selectively Target Tumor Cells, Spur Immune Attack

Researchers have developed an antibody, derived from patients with early-stage lung cancer, that enlists the immune system to destroy cancer cells.

The antibody killed tumor cells in cell lines of several different cancer types and slowed tumor growth in mouse models of brain and lung cancer without obvious evidence of side effects, the researchers reported May 5 in Cell Reports.

from Cancer via ola Kala on Inoreader http://ift.tt/1ZtiiHc
via IFTTT